Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04811027 · ClinicalTrials.gov registry record · Phase 2
Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC
A Phase 2 study, sponsored by Immutep S.A.S..
- Completed
- Registry status
- Phase 2
- Development phase
- 171
- Enrollment target
NCT04811027: Completed Phase 2 study, sponsored by Immutep S.A.S..
NCT04811027 is a Phase 2 study that has completed, run by Immutep S.A.S.. The registered enrollment target is 171 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (29% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04811027, a Phase 2 study, has completed, sponsored by Immutep S.A.S..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 171 participants
- Enrollment target
Study Summary
Evaluate the safety and efficacy of eftilagimod alpha in combination with pembrolizumab against pembrolizumab alone in 1st line metastatic or recurrent HNSCC with programmed death-ligand 1 (PD-L1) positive (combined positive score \[CPS\] ≥1) tumors, and determine the efficacy and safety of efti plus pembrolizumab in patients with PD-L1 negative tumors.
Interventions
- DRUG pembrolizumab (KEYTRUDA®)
- DRUG eftilagimod alpha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2021-08-27 |
| Est. Completion | 2025-11-05 |
| Phase | Phase 2 |
What the finished NCT04811027 record still lists
NCT04811027 is an interventional study that assigns participants to a tested intervention. The registered 171 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (29% higher).
The record links to 0 conditions, and to 2 interventions - of which pembrolizumab (KEYTRUDA®) is the first listed.
NCT04811027 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04811027 about?
NCT04811027 is a clinical study titled "Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC". Evaluate the safety and efficacy of eftilagimod alpha in combination with pembrolizumab against pembrolizumab alone in 1st line metastatic or recurrent HNSCC with programmed death-ligand 1 (PD-L1) positive (combined positive score \[CPS\] ≥1) tumors, and determine the efficacy and safety of efti plu...
What is the current status of trial NCT04811027?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 171 participants. The study started on 2021-08-27. Estimated completion is 2025-11-05.
What interventions are being tested in trial NCT04811027?
The interventions under investigation include: pembrolizumab (KEYTRUDA®) (DRUG), eftilagimod alpha (DRUG).
Who is sponsoring clinical trial NCT04811027?
This trial is sponsored by Immutep S.A.S., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04811027's enrollment target sits among peer trials
171 398th of 2000 higher than 1,602 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02641145 · 171 participants · NA
Molecular Imaging of Primary Amyloid Cardiomyopathy
- NCT05541029 · 171 participants · NA
Music Listening: A Mechanistic Trial
- NCT05561127 · 171 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel
- NCT05592938 · 171 participants · NA
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI